The ACCOAST trial

Following presentation of the ACCOAST trial at the ESC Congress 2013 two of our members discuss questions raised from the findings.  Is time to reconsider pretreatment with P2Y12 receptor inhibitors in NSTE-ACS?  Jean-Philippe Collet (FR)  
Is upstream DAPT in NSTEACS dead or alive?  Leonardo Bolognese (IT)

Topics:
Acute Coronary Syndromes (ACS)

Source: ESC News and Press - March 17, 2014 Category: Cardiology Source Type: news